National poll highlights bedtime battles and sleep struggles among young children

Re­gen­eron, the 35-year-old drug­mak­er still led by its co-founders, is get­ting in­to the ven­ture in­vest­ing are­na. The New York phar­ma will com­mit $100 mil­lion per

Re­genxbio shared ear­ly bio­mark­er re­sults from a 12-year-old boy with Duchenne mus­cu­lar dy­s­tro­phy who re­ceived a high­er dose of its gene ther­a­py, and the biotech